Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The mRNA Writing On The Wall, GSK Expands CureVac Alliance Into Next-Gen COVID-19 Vaccines

Includes 100m Dose Boost To CureVac's COVID-19 Manufacturing

Executive Summary

After major setbacks to its existing COVID-19 vaccine platform, GSK is expanding its presence in mRNA, which increasingly looks to be the future.

You may also be interested in...



Sanofi Creates ‘Center Of Excellence’ In Pursuit Of mRNA Vaccine Rivals

Sanofi is beefing up its investment in mRNA vaccine technology with a 400m annual injection into a dedicated mRNA Center of Excellence as it seeks to be at the forefront of the next generation of candidates.

GSK Has Big Ambitions In Vaccines, With An Eye On Blockbuster Opportunities

The company is focusing on new technologies, including mRNA, and expects the vaccines business to deliver a high single-digit sales CAGR over the next five years.

A Vaccines Renaissance, Spurred By COVID-19, Is Underway

The pandemic has reignited interest and investment in vaccines across a wide array of disease areas by big pharma and venture investors, a panel of BIO experts said.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel